CD274 and non-small cell lung carcinoma: Even in cancer types where PD-L1 has a key role in the decisional treatment algorithm, such as NSCLC, it is considered an imperfect biomarker since tumor responses occur even in patients with low or absent PD-L1 expression, and poor outcomes are not uncommon even in patients with high PD-L1 expression of ≥50%.